Literature DB >> 10871320

Microinjection of nociceptin (Orphanin FQ) into nucleus tractus solitarii elevates blood pressure and heart rate in both anesthetized and conscious rats.

L Mao1, J Q Wang.   

Abstract

The role of nociceptinergic transmission in the nucleus tractus solitarii (NTS) in the central modulation of cardiovascular activity was investigated in pentobarbital-anesthetized and conscious rats. Pharmacological activation of nociceptin receptors with a unilateral injection of synthetic nociceptin into the NTS, wherein injection of L-glutamate (1 nmol) caused typical depressor responses, elevated blood pressure and heart rate (HR) in most of the anesthetized rats. The elevation of blood pressure and HR by nociceptin was dose-dependent (0.04, 0.2, and 1 nmol) with a threshold dose of 0.2 nmol. At 1 nmol, changes in blood pressure and HR were evident at 5 min, and remained for 45 min after injection. Pretreatment with the selective nociceptin receptor antagonist nocistatin (1 nmol) into the NTS abolished the nociceptin-induced hypertension and tachycardia. In contrast, the nonselective opioid receptor antagonist naloxone (5 nmol) did not modify the cardiovascular responses to nociceptin. Intra-NTS injection of nocistatin (0.04 and 1 nmol) and naloxone alone had no significant effect on baseline blood pressure and HR. In chronically cannulated and conscious rats, similar pressor and tachycardic responses were induced by intra-NTS injection of 1 nmol of nociceptin. However, changes in blood pressure and HR were rapid, and quickly returned to normal levels within 10 min. These data suggest that the newly discovered nociceptinergic transmission in the NTS has a powerful influence on peripheral hemodynamic activity. This influence is inhibitory and may not be tonically active under normal physiological conditions. Moreover, the cardiovascular responses to exogenous nociceptin were mediated through activation of specific nociceptin receptors rather than typical naloxone-sensitive opioid receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871320

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Role of lateral parabrachial opioid receptors in exercise-induced modulation of the hypotensive hemorrhage response in conscious male rats.

Authors:  Joslyn K Ahlgren; Linda F Hayward
Journal:  Behav Brain Res       Date:  2011-10-01       Impact factor: 3.332

2.  Brain opioid and nociceptin receptors are involved in regulation of bombesin-induced activation of central sympatho-adrenomedullary outflow in the rat.

Authors:  Toshio Yawata; Youichirou Higashi; Takahiro Shimizu; Shogo Shimizu; Kumiko Nakamura; Keisuke Taniuchi; Tetsuya Ueba; Motoaki Saito
Journal:  Mol Cell Biochem       Date:  2015-10-01       Impact factor: 3.396

3.  Regulation of cyclin-dependent kinase 5 and casein kinase 1 by metabotropic glutamate receptors.

Authors:  F Liu; X H Ma; J Ule; J A Bibb; A Nishi; A J DeMaggio; Z Yan; A C Nairn; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

4.  Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux.

Authors:  Bruno D'Agostino; Giuseppina Marrocco; Marilisa De Nardo; Girolamo Calò; Remo Guerrini; Luca Gallelli; Charles Advenier; Francesco Rossi
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

5.  Pharmacological characterization of inhibitory effects of postsynaptic opioid and cannabinoid receptors on calcium currents in neonatal rat nucleus tractus solitarius.

Authors:  Takayuki Endoh
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

6.  Nociceptin inhibits airway microvascular leakage induced by HCl intra-oesophageal instillation.

Authors:  Céline Rouget; Yong Yao Cui; Bruno D'Agostino; Christophe Faisy; Emmanuel Naline; Marc Bardou; Charles Advenier
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.